Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15533598 | 0.88 | EPHX2 (0.52) | EPHX2SLC6A2SLC6A4HTR1AHTR2C | |
| SCHEMBL31652008 | 0.87 | EPHX2 (0.49) | EPHX2SLC6A2HTR1AHTR2C | |
| SCHEMBL4317786 | 0.83 | MAPT (0.49) | EPHX2SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL31651997 | 0.82 | EPHX2 (0.56) | EPHX2SLC6A2SLC6A4HTR1AHTR2C | |
| SCHEMBL1026306 | 0.82 | CYP2C19 (0.57) | EPHX2SLC6A2HTR1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL1969103 | 0.81 | LMNA (0.58) | EPHX2SLC6A2HTR1AKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL30069211 | 0.81 | LMNA (0.58) | EPHX2SLC6A2HTR1AKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL26600676 | 0.81 | LMNA (0.58) | EPHX2SLC6A2HTR1AKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL30069213 | 0.81 | LMNA (0.58) | EPHX2SLC6A2HTR1AKDM4EALDH1A1 | |
| SCHEMBL3882059 | 0.79 | EPHX2 (0.49) | EPHX2SLC6A2SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2847193-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190031685-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-01-31 | — | — | US | disclosed |
| US-9951088-B2 | D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-2847193-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20150072974-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2015-03-12 | — | — | US | disclosed |
| WO-2013169964-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072974-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, SNCA, KYNU | EPHX2 1951/4885SLC6A2 294/4885SLC6A4 378/4885 |
| US-20190031685-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, SNCA, KYNU | EPHX2 1951/4885SLC6A2 294/4885SLC6A4 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.